Abstract Search

ea0098c28 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging | NANETS2023

ETCTN 10450: A phase I trial of peposertib and lutetium 177 DOTATATE in well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Chauhan Aman , Kolesar Jill , Yan Donglin , Li Daneng , Khurana Aman , Edgar Carson William , Arnold Susanne M. , Gore Steven , Rubinstein Larry , Kohn Elise C. , Percy Ivy S. , Xiao Ying , Dewaraja Yuni , Soares Heloisa P. , Hendrik Beumer Jan , Konda Bhavana , Sukrithan Vineeth , Brian Anthony Lowell

Background: Radiolabeled somatostatin analogs provide a means of delivering targeted radiation with a high therapeutic index to NETs that express somatostatin receptors (SSTRs). We hypothesize that the addition of an effective radiation sensitizer could help improve the antitumor activity of Lutathera. Radiation is a potent inducer of DNA damage. The primary repair mechanism of radiation-induced double-stranded breaks (DSBs) is the nonhomologous end-joining (NHEJ) pathway, in ...

0 shares

Endocrine Abstracts

ETCTN 10450: A phase I trial of peposertib and lutetium 177 DOTATATE in well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

BiosciAbstracts